ATyr Pharma Financials
| LIFE Stock | USD 1.60 0.02 1.23% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.81 | 6.2739 |
|
|
The financial analysis of ATyr Pharma is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for ATyr Pharma includes many different criteria found on its balance sheet. For example, investors should never minimize ATyr Pharma's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor ATyr Pharma's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in ATyr Pharma.
Net Income |
|
With this module, you can analyze ATyr financials for your investing period. You should be able to track the changes in ATyr Pharma individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
ATyr | Select Account or Indicator |
Understanding current and past ATyr Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ATyr Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in ATyr Pharma's assets may result in an increase in income on the income statement.
The data published in ATyr Pharma's official financial statements usually reflect ATyr Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of aTyr Pharma. For example, before you start analyzing numbers published by ATyr accountants, it's critical to develop an understanding of what ATyr Pharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of ATyr Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ATyr Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ATyr Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of aTyr Pharma. Please utilize our Beneish M Score to check the likelihood of ATyr Pharma's management manipulating its earnings.
ATyr Pharma Stock Summary
ATyr Pharma competes with Mereo BioPharma, Terns Pharmaceuticals, PDS Biotechnology, Inozyme PharmaInc, and Hookipa Pharma. aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company was incorporated in 2005 and is headquartered in San Diego, California. Atyr Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US0021202025 |
| CUSIP | 002120103 002120202 |
| Location | California; U.S.A |
| Business Address | 10240 Sorrento Valley |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.atyrpharma.com |
| Phone | 858 731 8389 |
| Currency | USD - US Dollar |
You should never invest in ATyr Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of ATyr Stock, because this is throwing your money away. Analyzing the key information contained in ATyr Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
ATyr Pharma Key Financial Ratios
Generally speaking, ATyr Pharma's financial ratios allow both analysts and investors to convert raw data from ATyr Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of ATyr Pharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that aTyr Pharma reports annually and quarterly.| Return On Equity | -0.62 | ||||
| Operating Margin | (155.58) % | ||||
| Price To Sales | 334.89 X |
ATyr Pharma Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 36.2M | 38.7M | 115.5M | 95.8M | 122.1M | 116.0M | |
| Other Current Liab | 2.4M | 3.6M | 4.0M | 9.9M | 23.1M | 40.5M | |
| Net Tangible Assets | 21.2M | 31.7M | 109.1M | 71.5M | 82.2M | 86.3M | |
| Retained Earnings | (322.3M) | (338.5M) | (372.3M) | (417.6M) | (468.0M) | (444.6M) | |
| Accounts Payable | 847K | 1.4M | 1.0M | 3.1M | 3.5M | 3.4M | |
| Cash | 9.2M | 17.0M | 2.3M | 10.0M | 22.5M | 21.4M | |
| Other Current Assets | 781K | 2.0M | 5.4M | 3.0M | 2.4M | 2.3M | |
| Total Liab | 15.2M | 7.2M | 6.4M | 24.5M | 31.6M | 30.0M | |
| Total Current Assets | 31.9M | 35.7M | 113.7M | 81.1M | 103.0M | 97.8M | |
| Short Term Debt | 9.5M | 861K | 980K | 894K | 1.3M | 1.3M | |
| Common Stock | 4K | 11K | 28K | 29K | 63K | 59.9K | |
| Other Assets | 172K | 1K | 158K | 3.4M | 1.0 | 0.95 |
ATyr Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ATyr Pharma's current stock value. Our valuation model uses many indicators to compare ATyr Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ATyr Pharma competition to find correlations between indicators driving ATyr Pharma's intrinsic value. More Info.aTyr Pharma is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . At present, ATyr Pharma's Return On Equity is projected to slightly decrease based on the last few years of reporting.Comparative valuation analysis is a catch-all model that can be used if you cannot value ATyr Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ATyr Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ATyr Pharma's earnings, one of the primary drivers of an investment's value.aTyr Pharma Systematic Risk
ATyr Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ATyr Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on aTyr Pharma correlated with the market. If Beta is less than 0 ATyr Pharma generally moves in the opposite direction as compared to the market. If ATyr Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one aTyr Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ATyr Pharma is generally in the same direction as the market. If Beta > 1 ATyr Pharma moves generally in the same direction as, but more than the movement of the benchmark.
About ATyr Pharma Financials
What exactly are ATyr Pharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include ATyr Pharma's income statement, its balance sheet, and the statement of cash flows. Potential ATyr Pharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although ATyr Pharma investors may use each financial statement separately, they are all related. The changes in ATyr Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ATyr Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze ATyr Pharma Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as ATyr Pharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of ATyr has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if ATyr Pharma's financials are consistent with your investment objective using the following steps:- Review ATyr Pharma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand ATyr Pharma's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare ATyr Pharma's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if ATyr Pharma's stock is overvalued or undervalued.
Today, most investors in ATyr Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ATyr Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ATyr Pharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
ATyr Pharma April 19, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ATyr Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of aTyr Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of aTyr Pharma based on widely used predictive technical indicators. In general, we focus on analyzing ATyr Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ATyr Pharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.53 | |||
| Information Ratio | 0.0258 | |||
| Maximum Drawdown | 28.85 | |||
| Value At Risk | (6.01) | |||
| Potential Upside | 5.63 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in aTyr Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. For information on how to trade ATyr Stock refer to our How to Trade ATyr Stock guide.Note that the aTyr Pharma information on this page should be used as a complementary analysis to other ATyr Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for ATyr Stock analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is ATyr Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ATyr Pharma. If investors know ATyr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ATyr Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 0.007 | Quarterly Revenue Growth (1.00) | Return On Assets (0.32) | Return On Equity (0.62) |
The market value of aTyr Pharma is measured differently than its book value, which is the value of ATyr that is recorded on the company's balance sheet. Investors also form their own opinion of ATyr Pharma's value that differs from its market value or its book value, called intrinsic value, which is ATyr Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ATyr Pharma's market value can be influenced by many factors that don't directly affect ATyr Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ATyr Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ATyr Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ATyr Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.